$1.19
Revenue is down for the last 2 quarters, 69.20M → 62.44M (in $), with an average decrease of 9.8% per quarter
Netprofit is down for the last 2 quarters, -61.16M → -92.47M (in $), with an average decrease of 51.2% per quarter
In the last 1 year, 10x Genomics Inc has given 43.0% return, outperforming this stock by 109.4%
In the last 3 years, American Well Corporation has experienced a drawdown of -95.8%, however R1 Rcm Inc resisted the overall trend and outperformed by 30.2%
1.68%
Downside
Day's Volatility :4.1%
Upside
2.46%
1.68%
Downside
52 Weeks Volatility :73.35%
Upside
72.89%
Period | American Well Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -43.87% | -1.4% | 0.0% |
6 Months | -46.88% | 3.7% | 2.8% |
1 Year | -66.38% | 6.0% | 5.3% |
3 Years | -95.82% | 27.7% | 21.9% |
Market Capitalization | 424.2M |
Book Value | $2.2 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.23 |
Wall Street Target Price | 2.64 |
Profit Margin | -226.06% |
Operating Margin TTM | -94.27% |
Return On Assets TTM | -15.64% |
Return On Equity TTM | -69.18% |
Revenue TTM | 274.9M |
Revenue Per Share TTM | 0.99 |
Quarterly Revenue Growth YOY | -3.2% |
Gross Profit TTM | 116.8M |
EBITDA | -231.1M |
Diluted Eps TTM | -2.23 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.01 |
EPS Estimate Next Year | -0.75 |
EPS Estimate Current Quarter | -0.22 |
EPS Estimate Next Quarter | -0.21 |
What analysts predicted
Upside of 121.85%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 114.0M | - |
Net Income | -52.7M | - |
Net Profit Margin | -46.22% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 148.9M | ↑ 30.63% |
Net Income | -87.2M | ↑ 65.53% |
Net Profit Margin | -58.57% | ↓ 12.35% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 245.3M | ↑ 64.77% |
Net Income | -224.4M | ↑ 157.41% |
Net Profit Margin | -91.51% | ↓ 32.94% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 252.8M | ↑ 3.07% |
Net Income | -176.3M | ↓ 21.43% |
Net Profit Margin | -69.76% | ↑ 21.75% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 64.2M | ↓ 11.71% |
Net Income | -70.0M | ↑ 46.54% |
Net Profit Margin | -109.04% | ↓ 43.35% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 64.5M | ↑ 0.44% |
Net Income | -69.1M | ↓ 1.27% |
Net Profit Margin | -107.17% | ↑ 1.87% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 69.2M | ↑ 7.27% |
Net Income | -70.1M | ↑ 1.36% |
Net Profit Margin | -101.26% | ↑ 5.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 62.4M | - |
Net Income | -92.5M | - |
Net Profit Margin | -148.09% | - |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 489.3M | - |
Total Liabilities | 693.7M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 499.9M | ↑ 2.16% |
Total Liabilities | 780.7M | ↑ 12.54% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↑ 175.39% |
Total Liabilities | 130.4M | ↓ 83.29% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↑ 5.03% |
Total Liabilities | 185.0M | ↑ 41.79% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↓ 15.79% |
Total Liabilities | 133.7M | ↓ 27.71% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↓ 5.81% |
Total Liabilities | 153.0M | ↓ 17.27% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 4.65% |
Total Liabilities | 137.6M | ↓ 10.08% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 5.14% |
Total Liabilities | 126.9M | ↓ 7.74% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 1.15% |
Total Liabilities | 133.7M | ↑ 5.34% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 850.5M | ↓ 30.15% |
Total Liabilities | 136.2M | ↑ 1.89% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 772.2M | ↓ 9.21% |
Total Liabilities | 128.5M | ↓ 5.68% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -74.0M | - |
Investing Cash Flow | -245.9M | - |
Financing Cash Flow | 278.2M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -81.9M | ↑ 10.66% |
Investing Cash Flow | 120.0M | ↓ 148.79% |
Financing Cash Flow | 46.6M | ↓ 83.23% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -112.5M | ↑ 37.33% |
Investing Cash Flow | -66.8M | ↓ 155.63% |
Financing Cash Flow | 983.1M | ↑ 2007.93% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -141.5M | ↑ 25.85% |
Investing Cash Flow | -59.6M | ↓ 10.67% |
Financing Cash Flow | 5.8M | ↓ 99.41% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -62.2M | ↑ 38.44% |
Investing Cash Flow | -499.3M | ↑ 147619.23% |
Financing Cash Flow | -7.8M | ↓ 737.06% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -43.2M | ↓ 30.52% |
Investing Cash Flow | 123.0M | ↓ 124.64% |
Financing Cash Flow | 2.2M | ↓ 128.69% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -51.0M | ↑ 17.98% |
Investing Cash Flow | 124.9M | ↑ 1.54% |
Financing Cash Flow | 1.5M | ↓ 32.55% |
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() American Well Corporation | -11.19% | -46.88% | -66.38% | -95.82% | -94.84% |
![]() R1 Rcm Inc | -5.52% | 13.31% | -17.17% | 3.73% | 59.96% |
![]() 10x Genomics Inc | -13.37% | -15.68% | 43.03% | -65.63% | -21.61% |
![]() Veeva Systems Inc. | 8.28% | 16.7% | 24.96% | -24.92% | 93.21% |
![]() Ge Healthcare Technologies Inc. | -6.75% | -15.03% | 6.35% | 6.35% | 6.35% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() American Well Corporation | NA | NA | NA | -2.01 | -0.69 | -0.16 | 0.0 | 2.2 |
![]() R1 Rcm Inc | 128.18 | NA | 0.77 | 0.06 | -0.02 | 0.02 | 0.0 | 6.55 |
![]() 10x Genomics Inc | NA | NA | NA | -1.69 | -0.22 | -0.11 | 0.0 | 6.76 |
![]() Veeva Systems Inc. | 61.02 | 61.02 | 1.27 | 4.18 | 0.15 | 0.05 | 0.0 | 25.85 |
![]() Ge Healthcare Technologies Inc. | 19.51 | 19.51 | NA | 3.8 | 0.15 | 0.06 | 0.0 | 15.62 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() American Well Corporation | Hold | $424.2M | -94.84% | NA | -226.06% |
![]() R1 Rcm Inc | Buy | $6.3B | 59.96% | 128.18 | -3.09% |
![]() 10x Genomics Inc | Buy | $6.3B | -21.61% | NA | -30.31% |
![]() Veeva Systems Inc. | Buy | $32.6B | 93.21% | 61.02 | 24.2% |
![]() Ge Healthcare Technologies Inc. | Buy | $31.5B | 6.35% | 19.51 | 9.62% |
RIMA MANAGEMENT, LLC
Vanguard Group Inc
BlackRock Inc
Caledonia (Private) Investments Pty Ltd
SATTER MANAGEMENT CO., L.P.
State Street Corporation
American Well Corporation’s price-to-earnings ratio stands at None
Read Moreamwell (previously known as american well) is a leading telehealth platform in the united states and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. amwell believes that digital care delivery will transform healthcare. the company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, behavioral health, as well as chronic care management and healthy living. with over a decade of experience, amwell powers telehealth solutions for over 240 health systems comprised of 2,000 hospitals and 55 health plan partners with over 36,000 employers, reaching over 80 million lives.
Organization | American Well Corporation |
Employees | 1123 |
CEO | Dr. Ido Schoenberg M.D. |
Industry | Technology Services |
Virtus Dividend, Interest & Premium Strategy Fund
$1.19
+0.0%
Primis Financial Corp
$1.19
+0.0%
Diversified Healthcare Trust
$1.19
+0.0%
Calamp Corp.
$1.19
+0.0%
Orthofix Medical Inc
$1.19
+0.0%
Nextgen Healthcare, Inc.
$1.19
+0.0%
Spdr Ftse International Gove
$1.19
+0.0%
Teucrim Soybean Fund
$1.19
+0.0%
Farmers National Banc Corp
$1.19
+0.0%